(161 days)
Not Found
No
The document describes a standard monitor/defibrillator with various physiological monitoring capabilities and does not mention any AI or ML components.
Yes
The device provides therapy functions such as manual defibrillation to terminate potentially fatal arrhythmias, noninvasive pacing for symptomatic bradycardia, and automated external defibrillation. These functions directly treat medical conditions.
Yes
The device performs several functions for identifying and diagnosing conditions, such as 12-lead electrocardiogram for cardiac disorders, pulse oximetry for hypoxemia, noninvasive blood pressure monitoring for hypertension/hypotension, and invasive pressure monitoring to aid in medical diagnosis.
No
The device description clearly states it is a "monitor/defibrillator," which is a hardware device with integrated software, not a software-only medical device.
Based on the provided text, the LIFEPAK 15 monitor/defibrillator is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens derived from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- LIFEPAK 15 Function: The LIFEPAK 15 is a device that directly interacts with the patient's body through electrodes, sensors, and cuffs to monitor physiological signals (ECG, SpO2, NIBP, EtCO2, invasive pressure) and deliver therapy (defibrillation, pacing). It does not analyze samples taken from the body.
The device's functions are focused on real-time patient monitoring and intervention, which falls under the category of patient-contact medical devices, not IVDs.
N/A
Intended Use / Indications for Use
The LIFEPAK 15 monitor/defibrillator is intended for use by trained medical personnel in out-of doors and indoor emergency care settings within the environmental conditions specified. The LIFEPAK 15 monitor/defibrillator is designed to be used during ground transportation except when specified otherwise. Manual mode monitoring and therapy functions are intended for use on adult and pediatric patients. Automated external defibrillation mode is intended for use on patients eight years of age and older.
Manual defibrillation is indicated for the termination of certain potentially fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA), such as idioventricular or ventricular escape rhythms, and in the treatment of asystole.
AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm. In AED mode, the LIFEPAK 15 monitor/defibrillator is not intended for use on pediatric patients less than eight years old.
Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
The 12-lead electrocardiogram is used to identify, diagnose and treat patients with cardiac disorders and is useful in the early detection and prompt treatment of patients with acute ST-elevation myocardial infarction (STEMI).
Pulse oximetry is indicated for use in any patient who is at risk of developing hypoxemia, carboxyhemoglobinemia, or methemoqlobinemia. SpO2 monitoring may be used during no motion and motion conditions, and in patients who are well or poorly perfused. SpCO and SpMet accuracies have not been validated under motion or low perfusion conditions.
Noninvasive blood pressure monitoring is intended for detection of hypertension or hypotension and monitoring BP trends in patient conditions such as, but not limited to, shock, acute dysrhythmia, or major fluid imbalance.
EtCO2 monitoring is used to detect trends in the level of expired CO2. It is used for monitoring breathing efficacy and treatment effectiveness in acute cardiopulmonary care, for example, to determine if adequate compressions are being performed during CPR or to rapidly detect whether an endotrachea! tube has been placed successfully.
Invasive pressure monitoring is indicated for use in patients who require continuous monitoring of physiological pressures in order to rapidly assess changes in the patient's condition or response to therapy. It may also be used to aid in medical diagnosis.
Product codes
MKJ, LDD, DRT, DRO, DQA, DXN, DSK, CCK
Device Description
The LIFEPAK 15 monitor/defibrillator is a complete acute cardiac care response system designed for basic life support (BLS) and advanced life support (ALS) patient management protocols.
The LIFEPAK 15 monitor/defibrillator product is a next generation product to the currently legally marketed LIFEPAK 12 defibrillator/ monitor product. The LIFEPAK 15 monitor/defibrillator design is significantly based upon the existing LIFEPAK 12 architecture and when compared to the LIFEPAK 12 predicate it has similar performance characteristics, features, and accessories.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Manual mode monitoring and therapy functions are intended for use on adult and pediatric patients. Automated external defibrillation mode is intended for use on patients eight years of age and older. In AED mode, the LIFEPAK 15 monitor/defibrillator is not intended for use on pediatric patients less than eight years old.
Intended User / Care Setting
trained medical personnel in out-of doors and indoor emergency care settings
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
This 510(k) includes documentation related to the verification and validation of the LIFEPAK 15 monitor/defibrillator.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K063510, K041459, K040775, K033275, K010918, K002445, K990338, K991910, K973486
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5310 Automated external defibrillator system.
(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
K082937
r1/4
MAR 1 1 2009
(Optional Format 3-10-98)
| 510(k) Summary | This summary of 510(k) safety and effectiveness information is being submitted
in accordance with the requirements of 21 C.F.R. § 807.92. | | |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|----------|--|
| Submitter | Physio - Control, Inc.
11811 Willow Road Northeast
P.O. Box 97006
Redmond, Washington 98073-9706
Registration Number: 3015876 and 3006703820 | | |
| Contact Person | Teresa Davidson
Telephone: (425) 867-4733
Fax: (425) 867-4154
email: teresa.davidson@medtronic.com | | |
| Date Prepared | March 2, 2009 | | |
| Name | LIFEPAK® 15 Monitor/ Defibrillator | | |
| Common Name | Low Energy DC - Defibrillator: Class II | | |
| Device
Classification | Classification Name | Class | |
| | Low-Energy DC - Defibrillators | Class II | |
SECTION E - 510(k) SUMMARY
| Classification Name | Class |
|---|---|
| Low-Energy DC - Defibrillators | Class II |
| Cardiac Monitors (including Cardiotachometer | |
| and Rate Alarms | Class II |
| External Transcutaneous Cardiac (non- | |
| invasive) Pacemaker | Class II |
| Oximeter | Class II |
| Automated External Defibrillator | Class III |
| Noninvasive Blood Pressure Measurement | |
| System | Class II |
| Blood Pressure Computer | Class II |
| Carbon Dioxide Gas Analyzer | Class II |
1
K082937
p.2/4
SECTION E: 510(k) SUMMARY
The features and functions of the LIFEPAK 15 monitor/defibrillator are Predicate Device(s) substantially equivalent to the previously cleared LIFEPAK 12 defibrillator/monitor. Listed in Table 1 are the respective 510(k) numbers and clearance dates.
| 510(k) Number | Clearance Date |
|---|---|
| K063510 | 01/26/07 |
| K041459 | 07/01/04 |
| K040775 | 04/23/04 |
| K033275 | 11/06/03 |
| K010918 | 03/26/01 |
| K002445 | 01/31/01 |
| K990338 | 09/01/99 |
| K991910 | 06/03/99 |
| K973486 | 01/09/98 |
Performance This 510(k) includes documentation related to the verification and validation of Standards the LIFEPAK 15 monitor/defibrillator. Device The LIFEPAK 15 monitor/defibrillator is a complete acute cardiac care response system designed for basic life support (BLS) and advanced life support (ALS) Description patient management protocols. Intended Use The LIFEPAK 15 monitor/defibrillator is intended for use by trained medical personnel in out-of doors and indoor emergency care settings within the environmental conditions specified. The LIFEPAK 15 monitor/defibrillator is designed to be used during ground transportation except when specified otherwise. Manual mode monitoring and therapy functions are intended for use on adult and pediatric patients. Automated external defibrillation mode is intended for use on patients eight years of age and older. Manual Defibrillation Indications for Use
Indications
Manual defibrillation is indicated for the termination of certain potentially fatal arrhythmias, such as ventricular fibrillation and symptomatic
2
K092937
p. 3/4
SECTION E: 510(k) SUMMARY
ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
Contraindications
Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA), such as idioventricular or ventricular escape rhythms, and in the treatment of asystole.
Automated External Defibrillation
Indications
AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm. In AED mode, the LIFEPAK 15 monitor/defibrillator is not intended for use on pediatric patients less than eight years old.
Noninvasive Pacing
Indications
Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Contraindications
Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
12-lead Electrocardiography
Indications
The 12-lead electrocardiogram is used to identify, diagnose and treat patients with cardiac disorders and is useful in the early detection and prompt treatment of patients with acute ST-elevation myocardial infarction (STEMI).
Pulse Oximetry
Indications
Pulse oximetry is indicated for use in any patient who is at risk of developing hypoxemia, carboxyhemoglobinemia, or methemoqlobinemia. SpO2 monitoring may be used during no motion and motion conditions, and in patients who are well or poorly perfused.
3
Image /page/3/Picture/0 description: The image shows handwritten text that appears to be an identifier or code, followed by a page number. The text "K082937" is written on the top line. Below that, the text "p. 4/4" is written, indicating page 4 of 4. The handwriting is somewhat stylized, with distinct letterforms.
SECTION E: 510(k) SUMMARY
SpCO and SpMet accuracies have not been validated under motion or low perfusion conditions.
Noninvasive Blood Pressure Monitoring
Indications
Noninvasive blood pressure monitoring is intended for detection of hypertension or hypotension and monitoring BP trends in patient conditions such as, but not limited to, shock, acute dysrhythmia, or major fluid imbalance.
End-Tidal CO2 monitoring
Indications
EtCO2 monitoring is used to detect trends in the level of expired CO2. It is used for monitoring breathing efficacy and treatment effectiveness in acute cardiopulmonary care, for example, to determine if adequate compressions are being performed during CPR or to rapidly detect whether an endotrachea! tube has been placed successfully.
Invasive Pressure Monitoring
Indications
Invasive pressure monitoring is indicated for use in patients who require continuous monitoring of physiological pressures in order to rapidly assess changes in the patient's condition or response to therapy. It may also be used to aid in medical diagnosis.
| Technological
Characteristics | The LIFEPAK 15 monitor/defibrillator product is a next generation product to the
currently legally marketed LIFEPAK 12 defibrillator/ monitor product. The
LIFEPAK 15 monitor/defibrillator design is significantly based upon the existing
LIFEPAK 12 architecture and when compared to the LIFEPAK 12 predicate it
has similar performance characteristics, features, and accessories. |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Conclusion | The information in this 510(k) demonstrates that the LIFEPAK® 15
Monitor/Defibrillator, is substantially equivalent to the identified predicate
devices with respect to safety, effectiveness and performance. |
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/4/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features an eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The eagle is facing to the left and has its talons extended. The seal is black and white.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAR 1 1 2009
Physio - Control, Inc c/o Ms. Teresa Davidson 11811 Willow Road Northeast P.O. Box 97006 Redmond, WA 98073-9706
Re: K082937
Lifepak 15 Regulation Number: 21 CFR 870.5310 Regulation Name: Automated External Defibrillator Regulatory Class: Class III (Three) Product Code: MKJ, LDD, DRT, DRO, DQA, DXN, DSK, CCK Dated: March 2, 2009 Received: March 4, 2009
Dear Ms. Davidson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2 - Ms. Teresa Davidson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance. please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
SECTION D - STATEMENT OF INDICATIONS FOR USE
510(k) Number (if known): K082937
Device Name: LIFEPAK® 15 Monitor/Defibrillator
Indications for Use:
Manual Defibrillation
Indications
Manual defibrillation is indicated for the termination of certain potentially fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia. Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and, in relatively stable patients, ventricular tachycardia.
Contraindications
Defibrillation is contraindicated in the treatment of Pulseless Electrical Activity (PEA), such as idioventricular or ventricular escape rhythms, and in the treatment of asystole.
Automated External Defibrillation
Indications
AED mode is to be used only on patients in cardiopulmonary arrest. The patient must be unconscious, pulseless, and not breathing normally before using the defibrillator to analyze the patient's ECG rhythm. In AED mode, the LIFEPAK 15 monitor/defibrillator is not intended for use on pediatric patients less than eight years old.
Noninvasive Pacinq
Indications
Noninvasive pacing is indicated for symptomatic bradycardia in patients with a pulse.
Contraindications
Noninvasive pacing is contraindicated for the treatment of ventricular fibrillation and asystole.
12-lead Electrocardiography
Indications
The 12-lead electrocardiogram is used to identify, diagnose and treat patients with cardiac disorders and is useful in the early detection and prompt treatment of patients with acute ST-elevation ration (STEMI).
(Division Sign-Off) Division of Cardiovascular Devices K082937 510(k) Number
7
SECTION D - STATEMENT OF INDICATIONS FOR USE
Pulse Oximetry
Indications
Pulse oximetry is indicated for use in any patient who is at risk of developing hypoxemia, carboxyhemoglobinemia, or methemoglobinemia. SpO2 monitoring may be used during no motion and motion conditions, and in patients who are well or poorly perfused. SpCO and SpMet accuracies have not been validated under motion or low perfusion conditions.
Noninvasive Blood Pressure Monitoring
Indications
Noninvasive blood pressure monitoring is intended for detection of hypertension or hypotension and monitoring BP trends in patient conditions such as, but not limited to, shock, acute dysrhythmia, or major fluid imbalance.
End-Tidal CO2 monitoring
Indications
EtCO2 monitoring is used to detect trends in the level of expired CO2. It is used for monitoring breathing efficacy and treatment effectiveness in acute cardiopulmonary care, for example, to determine if adequate compressions are being performed during CPR or to rapidly detect whether an endotracheal tube has been placed successfully.
Invasive Pressure Monitoring
Indications
Invasive pressure monitoring is indicated for use in patients who require continuous monitoring of physiological pressures in order to rapidly assess changes in the patient's condition or response to therapy. It may also be used to aid in medical diagnosis.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | (Optional Format 3-10-98) | |
|---|---|---|
| (Division Sign-Off) | ||
| Division of Cardiovascular Devices | ||
| 510(k) Number | K082937 |